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Objectives: We aimed to (1) describe the real-world treatment of UTIs in a T2DM 
population, (2) investigate UTI related healthcare resource use, (3) assess treat-
ment costs associated with UTI, and (4) identify factors which may predict UTI-
related treatment costs. MethOds: We analysed an anonymized dataset from a 
regional German healthcare fund (AOK PLUS) including all continuously insured 
T2DM-prevalent patients from 2010-2012. Health care resource use was reported 
per UTI episode. A UTI episode was identified through coded outpatient/inpatient 
UTI diagnoses (ICD-10 N39.0) and, in case of recurrent diagnoses, prescribed anti-
biotics for UTI treatment. Results: A total of 456,586 T2DM patients (mean age of 
73.8 years, 56.3% female, mean CCI of 7.3, mean observational period of 665.5 days) 
was included. We identified 48,337 UTI episodes. During an observed UTI episode, 
patients visited with a median/mean of 1.0/0.8 times a GP and 0.0/0.3 times an 
urologist. In 6.7% of the cases, an inpatient treatment was caused by a UTI with a 
median/mean length of stay of 7.0/8.7 days. In 74.8% of the observed UTI episodes, 
antibiotics labelled for this disease were prescribed (mean prescribed DDD 10.5 
days). Mean/median costs directly associated with UTI treatment (bottom-up costs) 
were 315.90€ /102.28€ per UTI episode. Factors significantly increasing UTI-related 
direct bottom costs were age, female gender, worse CKD status (5/5), CCI, and at 
least one previous UTI infection in the reference period. In an additional top-down 
cost analysis, annual all-cause cost per patient year were 5,519 € higher in the UTI 
group compared to T2DM patients not having experienced an UTI. This translated 
into a UTI-related marginal cost-increasing effect of 3,916€ per patient year in a 
multivariable Gamma regression analysis. cOnclusiOns: Given that worldwide 
increasing prevalence of T2DM, the incidence of UTI infection in T2DM represents 
substantial resource use/cost burden for healthcare systems.
PUK32
AUtosomAl Polycystic Kidney diseAse (AdPKd): costs And ResoURce 
UtilisAtion in the noRdic coUntRies
Eriksson D1, Karlsson L1, Eklund O1, Dieperink H2, Honkanen E3, Melin J4, Selvig K5, 
Lundberg J6
1Quantify Research, Stockholm, Sweden, 2Odense University Hospital, Odense, Denmark, 3Helsinki 
University Central Hospital, Helsinki, Finland, 4Uppsala University Hospital, Uppsala, Sweden, 
5Vestre Viken Hospital Trust, Drammen, Norway, 6Otsuka Pharma Scandinavia, Stockholm, 
Sweden
Objectives: There is limited real-world information on resource utilisation, costs 
and productivity in patients with ADPKD. The objective of this study was to esti-
mate the annual direct and indirect costs of patients with ADPKD by severity of the 
disease [chronic kidney disease (CKD) stages 1–3, 4–5, dialysis, and transplant recipi-
ents], and describe the resource utilisation during the 12-month period around dial-
ysis initiation and transplant procedure, respectively. MethOds: A cross-sectional 
study of ADPKD patients was undertaken April–December 2014 in Denmark, Finland, 
Norway and Sweden. Data on medical resource utilisation were extracted from med-
ical charts and patients were asked to complete a self-administered survey, which 
included the Work Productivity and Activity Impairment Questionnaire. Results: A 
total of 266 patients were contacted, 243 (91%) of whom provided consent to partici-
pate in the study. Average total annual costs amounted to € 9,919 in CKD 1–3, € 16,761 
in CKD 4–5, € 74,015 in dialysis patients and € 31,496 in transplant recipients. Indirect 
costs were substantial in earlier stages of the disease, accounting for 72% and 73% 
of total costs in the CKD 1–3 and CKD 4–5 strata, respectively. Direct medical costs 
amounted to € 60,514 in dialysis patients and € 17,773 in transplant recipients. Among 
those who were employed, the overall work productivity loss ranged between 9% 
in CKD stage 1–3 to 42% in dialysis patients. An average of 16.5 hospital days and 
10.4 outpatient visits were observed in the 12-month period around dialysis initia-
tion. Around the transplant procedure, the average number of hospital days and 
outpatient visits were 29.9 and 16.9, respectively. cOnclusiOns: ADPKD is a pro-
gressive disease associated with increasing costs as the patient progresses to CKD 
stage 4–5, dialysis and transplant. Substantial savings and productivity gains could 
be made by delaying the progression of ADPKD to end stage renal disease.
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Objectives: Aim of the present study was to evaluate, through the analysis of 
administrative databases, healthcare resource consumption and costs in charge 
to the Regional Health Service (RHS) for patients receiving kidney transplanta-
tion. MethOds: All data recorded in the regional administrative databases regard-
ing subjects resident in Lombardy (one of the Italian Regions, with about 9,700,000 
inhabitants) who received kidney transplantation in 2011 were extracted. Direct 
healthcare costs in charge to the RHS for these subjects for the 12 months preced-
ing and following transplantation were estimated (drugs, hospitalizations, diag-
nostic/therapeutic procedures). Results: In 2011, 276 subjects received kidney 
transplantation, 268 of which survived for the following 12 months. Administrative 
data were available for 264 of these subjects (67.8% males, mean age 49.4). Among 
those patients who survived one year after transplantation, the per-patient yearly 
cost before transplantation amounted to 36,746€ (11.6% for drugs, 81.2% for diag-
nostic/therapeutic procedures and 7.2% for hospitalizations). Dialysis accounted 
for 91% of all costs for diagnostic/therapeutic procedures. In the year following 
transplantation, the per-patient cost amounted to 43,806€ (25.8% for drugs, 15.8% 
for diagnostic/therapeutic procedures and 58.4% for hospitalizations). The average 
per-patient cost of transplantation intervention was 21,183€ (82.7% of total cost 
of hospitalizations). The average cost of the last year of life of those patients who 
died within 12 months after transplantation was 79,362€ /patient (68.1% of which 
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Objectives: Chronic kidney disease (CKD) has become a major public health 
problem in China. Two sample cities, Qingdao, which has been providing out-
patient service with CKD patients in non-dialysis phases, and Shenyang, which 
has not provided the service, are selected as samples to discuss the policy effect 
of out-patient medical insurance. MethOds: CKD patient data collected in medi-
cal insurance administrative agencies of two sample cities in 2009 and 2010 are 
analyzed through discriptive statistics and independent sample T-test. Results: 
1) For kidney dialysis (KD) patients, out-patient growth rates of Qingdao and 
Shenyang are 8.15% and 15.93% respectively, and average ages are 56.14 and 
57.67 (P= 0.516); in-patient growth rates of Qingdao and Shenyang are -5.28% and 
16.01% respectively, and average ages are 60.56 and 58.88 (p= 0.000). 2) For renal 
transplantated (RT) recipients, out-patient growth rates of Qingdao and Shenyang 
are 7.80% and 8.15% respectively, and average ages are 48.71 and 48.73 (p= 0.172); 
in-patient growth rates of Qingdao and Shenyang are -6.98% and 2.65% respec-
tively, and average ages are 46.79 and 50.44 (p= 0.000). 3) On medical insurance 
fund expenditure, expenditure growth rates of KD out-patients and in-patients 
of Qingdao are -4.80% and -11.59% respectively, and those of Shenyang are 22.51% 
and 36.52%; expenditure growth rates of out-patient and in-patient RT recipients 
of Qingdao are -5.50% and -25.60% respectively, and those of Shenyang are 6.48% 
and -3.79%. cOnclusiOns: 1) Out-patient insurance creates a positive effect on 
controlling the excessive growth of the number of KD patients, while the effect 
is not so significant on the number of RT recipients. 2) Out-patient insurance 
produces effective results on controlling the rapid growth of medical insurance 
fund expenditure scale of KD patients, while the effect is not so significant of RT 
recipients. 3) Average ages of KD patients have not been decreased effectively 
because of the short period of policy implementation.
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Objectives: The objective of this study was to establish current practice in TDM 
in K-Tx in a real-world clinical setting, and to develop a best-practice concept to 
improve patient care. MethOds: TDM processes for transplanted patients were col-
lected at 13 centers in 5 countries between January 2015 and June 2015. More than 35 
Interviews with physicians, nurses and lab assistants were combined with observa-
tion of relevant steps during standard examination sessions. Duration of each main 
step to adjust the patient medication dose was recorded. Also dependencies from 
outside variables were recorded. Results: Several process patterns were identified. 
Main observed differences among centers were process steps and inefficiencies in 
exam setup and time required getting test results. The time gap between taking blood 
samples and availability of results leads to long patient stay and/or multiple visits or 
contacts with the patient (blood test, examination, result communication). Average 
time for patients in a center was 2:12 hours with a large range from 0:49 hours to 
6:22 hours. Process time for blood drawing, examinations and results communica-
tion (excluding lab processing) was on average 30 min ranging from 12 min to 52 
min. Complexity and time to get the results could be improved if a near-patient-test 
(NPT) scenario would be available while others are subject to normal process improve-
ments. cOnclusiOns: Results suggest that improvements could be made in all types 
of scenarios. Especially fast availability of test results in a NPT scenario could reduce 
complexity and facilitate the development of an improved process setup.
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Objectives: The aim of our study is to analyse the biosimilar bids of the Hungarian 
National Health Insurance Fund Administration in case of erythropoietin (ESA) prod-
ucts. MethOds: Data derived from the nationwide pharmaceutical database of 
Hungarian National Health Insurance Fund Administration. We analysed how the 
number of patients treated by erythropoietin products changed before (01.07.2011.-
30.06.2012.) and after (01.07.2012.-30.06.2013.) the first biosimilar bid performed 
in March 2012 in Hungary. Results: In the 12 months before biosimilar bid 4,482 
patients received erythropoietin treatment, while in the first 12 months after the bid 
4,545 patients, resulting in a 1.4 % increase. The second 12 months after the bid 4,644 
patients received erythropoietin treatment, resulting in a 3.6 % increase. Before the 
biosimilar bid, the NHIFA spent 2.33 billion Hungarian Forint (HUF) health insurance 
reimbursement for ESA products, which decreased by 47 % to 1.23 billion HUF in the 
first year after biosimilar bid. cOnclusiOns: The analyses of the Hungarian price 
competition bid of biosimilar products showed a minimal decline in the number of 
patients under treatment by erythropoietin products while the health insurance 
reimbursement of these drugs significantly decreased.
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